Aker Biomarine AS (AKBM) - Total Liabilities

Latest as of June 2025: Nkr237.50 Million NOK ≈ $24.99 Million USD

Based on the latest financial reports, Aker Biomarine AS (AKBM) has total liabilities worth Nkr237.50 Million NOK (≈ $24.99 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Aker Biomarine AS - Total Liabilities Trend (2016–2024)

This chart illustrates how Aker Biomarine AS's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Aker Biomarine AS to evaluate short-term liquidity relative to the company's equity base.

Aker Biomarine AS Competitors by Total Liabilities

The table below lists competitors of Aker Biomarine AS ranked by their total liabilities.

Company Country Total Liabilities
Jiangxi Sanchuan Water Meter
SHE:300066
China CN¥505.08 Million
SolGold Plc
F:S8F
Germany €254.44 Million
New Pacific Metals Corp
TO:NUAG
Canada CA$1.06 Million
Sipef NV
BR:SIP
Belgium €167.17 Million
Aeva Technologies, Inc. Common Stock
NYSE:AEVA
USA $45.74 Million
Ningxia Building Materials Group Co Ltd
SHG:600449
China CN¥1.60 Billion
Sichuan Zigong Conveying Machine Group Co Ltd
SHE:001288
China CN¥3.28 Billion
Metalurgica Gerdau S.A
SA:GOAU3
Brazil R$28.08 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Aker Biomarine AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Aker Biomarine AS market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.62 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.26 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.59 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.61 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Aker Biomarine AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Aker Biomarine AS (2016–2024)

The table below shows the annual total liabilities of Aker Biomarine AS from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 Nkr213.50 Million
≈ $22.47 Million
-53.65%
2023-12-31 Nkr460.60 Million
≈ $48.47 Million
+3.32%
2022-12-31 Nkr445.80 Million
≈ $46.91 Million
+15.16%
2021-12-31 Nkr387.12 Million
≈ $40.74 Million
+18.29%
2020-12-31 Nkr327.26 Million
≈ $34.44 Million
-39.13%
2019-12-31 Nkr537.68 Million
≈ $56.58 Million
+113.84%
2018-12-31 Nkr251.43 Million
≈ $26.46 Million
-20.96%
2017-12-31 Nkr318.12 Million
≈ $33.47 Million
+54.94%
2016-12-31 Nkr205.32 Million
≈ $21.61 Million
--

About Aker Biomarine AS

OL:AKBM Norway Packaged Foods
Market Cap
$906.28 Million
Nkr8.61 Billion NOK
Market Cap Rank
#9517 Global
#67 in Norway
Share Price
Nkr98.20
Change (1 day)
+1.97%
52-Week Range
Nkr57.20 - Nkr113.40
All Time High
Nkr113.40
About

Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LY… Read more